Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel (National Cancer Institute)
- Development stage
- Preclinical
- Lead developer
- Cook Medical
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
**Paclitaxel** is a taxane small-molecule microtubule stabilizer. In the Skåne University Hospital dialysis-access study, it was delivered locally from a paclitaxel-eluting angioplasty balloon during percutaneous treatment of stenotic native upper-extremity arteriovenous fistulas and graft-vein anastomoses. Local antiproliferative exposure is intended to limit neointimal hyperplasia and restenosis following balloon angioplasty. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05173857))
- Brand names
- Taxol
- Other names
- paclitaxelPTX
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel (National Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel (National Cancer Institute).